Market revenue in 2023 | USD 1,895.1 million |
Market revenue in 2030 | USD 10,561.3 million |
Growth rate | 27.8% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.22% in 2023. Horizon Databook has segmented the U.S. cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Pharmaceutical companies are increasingly outsourcing their development & manufacturing activities to CDMOs to reduce costs, accelerate time-to-market, and access specialized expertise. This trend is expected to drive the cell and gene therapy CDMO market growth across the U.S.
This expansion includes investments in new facilities, equipment upgrades, mergers & acquisitions, and process improvements. For instance, in September 2023, Apprentice.io partnered with Minaris Regenerative Medicine, a leading CDMO for cell & gene therapies, to implement the Tempo Manufacturing Execution System (MES).
This initiative strengthens Minaris’ competitive position and promotes market growth. Some of the key companies providing pharmaceutical CDMO services in the U.S. are Catalent, Inc., Lonza, Aenova Group, AbbVie, Inc., and Adare Pharma Solutions. The growing presence of these companies expanding their manufacturing facilities to cater to the rising demand for pharmaceuticals is likely to propel market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account